Pacira BioSciences reported new real-world findings showing that EXPAREL, its liposomal bupivacaine formulation for postsurgical pain management, was associated with lower opioid consumption, fewer opioid-related adverse events, and reduced healthcare costs among Medicare Advantage patients undergoing outpatient total shoulder arthroplasty. The retrospective study, presented at the 2026 ISPOR annual meeting, evaluated more than 6,400 opioid-naïve patients between 2019 and 2024 and compared EXPAREL-based pain protocols with standard analgesic approaches across a 90-day postoperative period.

Why orthopedic surgery is becoming a major proving ground for value-based non-opioid pain management models

The announcement matters less because it changes the clinical profile of EXPAREL and more because it reinforces a broader strategic transition occurring across orthopedic surgery and perioperative care economics. Hospitals, ambulatory surgery centers, and Medicare-focused provider systems are increasingly being evaluated not only on pain management outcomes, but also on opioid stewardship, readmission rates, recovery efficiency, and downstream cost control. In that environment, pharmaceutical companies seeking long-term positioning in postoperative care must demonstrate measurable economic value alongside clinical efficacy.

Pacira BioSciences appears to be leaning heavily into that evolving healthcare framework. The company’s emphasis on lower healthcare costs and reduced opioid-related complications reflects a deliberate effort to position EXPAREL as part of a value-based care solution rather than simply a premium analgesic product. Industry observers note that this distinction has become increasingly important as health systems face rising financial pressure tied to bundled payments, outpatient migration trends, and broader utilization scrutiny.

Orthopedic surgery has emerged as one of the clearest battlegrounds for these reimbursement and cost-efficiency debates. Procedures such as total shoulder arthroplasty continue rising alongside aging population trends, while payers simultaneously push providers toward shorter recovery timelines and lower postoperative complication rates. As more joint replacement procedures shift into outpatient environments, providers are becoming increasingly sensitive to interventions capable of supporting discharge efficiency and reducing avoidable follow-up utilization.

How the NOPAIN Act and Medicare reimbursement changes are reshaping commercial incentives for EXPAREL

The company’s messaging arrives during a period of heightened policy focus surrounding non-opioid pain management access. The NOPAIN Act has drawn increased attention to reimbursement structures for non-opioid therapies within Medicare outpatient settings, creating a potentially more favorable commercial environment for products capable of demonstrating both clinical and economic benefit. Regulatory watchers suggest that pharmaceutical manufacturers are increasingly tailoring evidence-generation strategies toward payer economics rather than relying exclusively on traditional efficacy narratives.

That shift reflects broader changes occurring across value-based healthcare delivery models. Earlier generations of postoperative pain management discussions often focused primarily on pain scores and patient comfort. Today, healthcare systems are increasingly examining whether non-opioid interventions can reduce total episode-of-care costs while also minimizing opioid exposure risks and complication-related utilization.

For Pacira BioSciences, the emphasis on healthcare costs over a 90-day recovery period appears strategically calculated. The company is effectively attempting to move the conversation beyond upfront product acquisition pricing and toward downstream economic impact. That framing could become increasingly important as providers continue facing pressure to improve financial efficiency across orthopedic service lines.

Industry analysts note that outpatient orthopedic surgery economics are becoming substantially more complex as reimbursement rates tighten and hospital systems attempt to preserve procedural margins. Products capable of demonstrating measurable reductions in complications, readmissions, or follow-up utilization may therefore gain increasing commercial relevance despite premium pricing concerns.

Why retrospective claims-based orthopedic pain management studies may still fall short of payer and clinician evidence standards

Despite the favorable findings, important methodological limitations remain attached to the study. The analysis was retrospective and observational, meaning it can identify associations but cannot definitively establish causation. Claims-based research may also be influenced by institutional practice differences, surgeon preferences, patient selection dynamics, and variations in perioperative care pathways unrelated to EXPAREL itself.

Clinicians tracking perioperative pain management trends have increasingly emphasized the importance of prospective comparative evidence when evaluating premium non-opioid interventions. While real-world evidence can influence formulary positioning and payer negotiations, retrospective analyses generally carry less evidentiary weight than randomized controlled trials.

That distinction matters because EXPAREL now operates within a far more competitive and economically sensitive pain management environment than when it first entered the market. Multimodal analgesia protocols have matured significantly across orthopedic surgery, with hospitals increasingly combining nerve blocks, regional anesthesia techniques, generic local anesthetics, and enhanced recovery pathways to reduce opioid exposure.

As a result, Pacira BioSciences is no longer competing solely against opioid-heavy postoperative regimens. The company is increasingly competing against lower-cost multimodal protocols that many providers believe can achieve comparable recovery outcomes without requiring premium analgesic expenditures.

The study’s focus on outpatient total shoulder arthroplasty is strategically notable in that context. Shoulder replacement procedures often involve substantial postoperative pain management requirements, making them a meaningful testing ground for opioid-sparing recovery strategies. At the same time, outpatient migration trends are increasing operational pressure on providers to minimize recovery disruptions and avoid costly postoperative complications.

How adoption, pricing pressure, and hospital pharmacy economics could shape EXPAREL’s long-term trajectory

The broader commercial challenge for Pacira BioSciences centers on whether the company can continue proving differentiated value as healthcare systems intensify cost containment efforts. Adoption of EXPAREL has historically varied across hospitals depending on pharmacy budgets, payer coverage, surgeon familiarity, and institutional protocol design.

Some health systems continue questioning whether the incremental clinical and operational benefits associated with liposomal bupivacaine formulations justify the pricing premium compared with generic alternatives and evolving multimodal care strategies. That debate may become even more pronounced as hospitals continue facing margin compression pressures and aggressive pharmacy expenditure reviews.

Pacira BioSciences appears to recognize that reality clearly. The company’s latest ISPOR presentation focused heavily on health economics outcomes rather than solely emphasizing opioid reduction metrics or pain management efficacy. That suggests the company increasingly understands that long-term commercial durability may depend more on financial alignment with value-based care systems than on pharmacologic differentiation alone.

Regulatory dynamics may also continue supporting broader interest in real-world evidence generation. Healthcare policymakers and reimbursement agencies are placing greater emphasis on outcomes data reflecting routine clinical practice rather than tightly controlled trial settings alone. Pharmaceutical manufacturers across multiple therapeutic categories are increasingly using observational datasets to strengthen payer discussions and institutional purchasing negotiations.

What clinicians, regulators, and industry observers are likely to watch next for Pacira BioSciences

The next phase of scrutiny surrounding EXPAREL will likely center on whether Pacira BioSciences can generate additional prospective evidence supporting the economic findings presented in the current analysis. Prospective comparative studies evaluating recovery efficiency, complication reduction, and total episode-of-care costs across multiple orthopedic procedures could carry greater influence in payer negotiations than retrospective observational datasets alone.

Clinicians are also likely to monitor whether outpatient orthopedic adoption trends continue accelerating under reimbursement reforms favoring opioid-sparing approaches. If hospitals increasingly prioritize value-based perioperative care pathways, products capable of supporting operational efficiency and complication reduction may gain stronger institutional positioning.

At the same time, competitive pressure within the non-opioid pain management market is unlikely to ease. Hospitals continue refining enhanced recovery protocols while seeking lower-cost strategies capable of balancing pain control, discharge efficiency, and opioid stewardship goals. Pacira BioSciences must therefore continue proving that EXPAREL delivers additive clinical and economic value within increasingly sophisticated perioperative care ecosystems.

The broader significance of the latest study lies in how it reflects the changing priorities of modern postoperative medicine. Pain management products are increasingly being evaluated not just on their pharmacologic profile, but on their ability to reduce healthcare utilization, support outpatient surgical economics, and align with reimbursement systems increasingly centered on measurable value. Pacira BioSciences appears to be positioning EXPAREL directly within that transition.

  EXPAREL, Medicare Advantage, NOPAIN Act, Pacira BioSciences, total shoulder arthroplasty